Browse the search results

Page 2 of 454
    1. Cancer Biology
    2. Genes and Chromosomes

    Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy

    Simeon U Springer et al.
    The creation of a non-invasive assay for detecting urothelial cancer could have a profound impact on how we find and treat the disease.
    1. Cancer Biology
    2. Human Biology and Medicine

    The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer

    James D Joseph et al.
    GDC-0810 is a novel, orally bioavailable SERD that exhibits robust pre-clinical activity in models of ER+ breast cancer, including models of tamoxifen resistance, and those that express the ERα mutations, ER.Y537S and ER.D538G.
    1. Biochemistry and Chemical Biology
    2. Cancer Biology

    Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins

    Alexander J Martinko et al.
    Proteomics and functional genomics coupled to an antibody discovery pipeline revealed the influence of oncogenic RAS signaling on the cell-surface proteome and resulted in the discovery of potential therapeutic targets for RAS-driven cancers.
    1. Cancer Biology

    Bladder-cancer-associated mutations in RXRA activate peroxisome proliferator-activated receptors to drive urothelial proliferation

    Angela M Halstead et al.
    Bladder-cancer-associated RXRA mutations were found to stimulate urothelial proliferation through a mechanism susceptible to small molecule inhibitors of Peroxisome Proliferator-Activated Receptors, credentialing a new class of targetable drivers of bladder cancer.
    1. Cancer Biology

    Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers

    Ganesh V Raj et al.
    A novel first-in-class small molecule (ERX-11) that interacts with and disrupts the interactome of the estrogen receptor (ER), blocks the growth of ER-positive breast cancers, including those that are resistant to currently approved hormonal agents.
    1. Genes and Chromosomes
    2. Human Biology and Medicine

    Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer

    Sakari Vanharanta et al.
    Inactivation of a multifunctional RNA-binding protein can lead to the acquisition of pro-metastatic phenotypes, possibly by stabilizing large-scale transcriptomic changes that provide a selective advantage during cancer progression.
    1. Genomics and Evolutionary Biology

    Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer

    Young Seok Ju et al.
    Identifying 1,907 mitochondrial somatic mutations from 1,675 tumor tissues provides new insights into the causes and effects of the mitochondrial genome mutations found in human cancers.
    1. Cell Biology
    2. Human Biology and Medicine

    Phenotype-based cell-specific metabolic modeling reveals metabolic liabilities of cancer

    Keren Yizhak et al.
    Genome-scale metabolic modeling of individual cancer cells and healthy human cells identifies specific and selective metabolic vulnerabilities.
    1. Cancer biology
    2. Developmental Biology and Stem Cells

    A long non-coding RNA targets microRNA miR-34a to regulate colon cancer stem cell asymmetric division

    Lihua Wang et al.
    A novel long non-coding RNA targets microRNA miR-34a for epigenetic silencing and initiates asymmetric division of colon cancer stem cells.
    1. Genes and Chromosomes

    DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis

    Benjamin JM Taylor et al.
    Enzymes that remove amine groups from cytosine bases in DNA are likely involved in generating the clusters of mutations (kataegis) seen in breast cancer.